Keyphrases
Acquired Chemoresistance
14%
Aldehyde Dehydrogenase 2 (ALDH2)
14%
Associated Genes
14%
Cancer Growth
14%
CD133
14%
Cell Cycle Arrest
14%
Cell Death
14%
Cell Proliferation
14%
Cell Therapy
14%
Chemotherapy Resistance
14%
Cisplatin Treatment
14%
CSC Targeting
14%
ERK2
14%
Gynecological Cancer
14%
High-grade Serous Ovarian Cancer (HGSOC)
100%
Immediate Effect
14%
Immunoblotting
14%
Immunohistochemistry
14%
Lasting Effect
14%
Maintenance Therapy
14%
MEK-ERK Pathway
14%
MEK1
100%
Mouse Xenograft
14%
Non-adherent
14%
Ovarian Cancer
14%
Ovarian Cancer Cells
28%
Pathway Activation
14%
Pathway Activity
14%
Possible Mechanisms
14%
Proliferation Resistance
14%
Quantitative PCR
14%
Recurrence Rate
14%
Resistance Mechanisms
14%
Stem Cells
28%
Stemness
14%
Targeted Drugs
14%
Therapeutic Target
100%
Tram
14%
Trametinib
42%
Tumor Growth in Vivo
14%
Tumor Growth Rate
14%
Medicine and Dentistry
Aldehyde Dehydrogenase Isoenzyme 1
20%
Cancer Growth
20%
Cell Cycle Arrest
20%
Cell Cycle Checkpoint
20%
Cell Death
20%
Cell Proliferation
20%
Cisplatin
20%
Drug Delivery System
20%
Drug Resistance
20%
Female Genital Tract Cancer
20%
Immunoblotting
20%
Immunohistochemistry
20%
In Vitro
20%
Krukenberg Tumor
100%
Maintenance Therapy
20%
Mitogen Activated Protein Kinase 3
20%
Ovarian Cancer
20%
Ovarian Cancer Cell Line
20%
Ovarian Carcinoma Cell Line
20%
Quantitative Reverse Transcription Polymerase Chain Reaction
20%
Recurrence Risk
20%
Trametinib
60%
Tumor Progression
40%
Xenograft
20%
Pharmacology, Toxicology and Pharmaceutical Science
Aldehyde Dehydrogenase Isoenzyme 1
16%
Cancer Growth
16%
Cisplatin
16%
Drug Delivery System
16%
Drug Resistance
16%
Female Genital Tract Cancer
16%
Mitogen Activated Protein Kinase 3
16%
Ovary Cancer
33%
Ovary Carcinoma
100%
Recurrence Risk
16%
Trametinib
50%
Tumor Growth
33%
Western Blot
16%